

Center for Medicaid, CHIP and Survey & Certification

CMCS Informational Bulletin

DATE:	March 30,	2012
-------	-----------	------

FROM: Cindy Mann, Director Center for Medicaid, CHIP and Survey & Certification (CMCS)

SUBJECT: Medicaid Lead Screening and EQRO protocols

This Informational Bulletin is meant to inform you of a pending revision to our policy regarding lead screening for Medicaid-eligible children and an opportunity to comment on proposed changes to Medicaid Managed Care External Quality Review Protocols.

Medicaid Lead Screening

Although substantial improvements have been made in reducing lead in the environment, lead poisoning continues to be a significant problem for some low-income children. To improve screening of children most at risk for lead exposure, CMS plans to align its Medicaid lead screening policy with current recommendations of the Centers for Disease Control and Prevention (CDC). The new approach encourages targeted screening in States that have sufficient data to demonstrate that universal screening is not the most effective method of identifying exposure to lead. In addition to being consistent with CDC's recommendations, this change will allow States' limited resources to be targeted to children most needing the services.

The CDC outlined its new lead screening policy in a report entitled *Recommendations for Blood Lead Screening of Medicaid Eligible Children Ages 1-5 years: An Updated Approach to Targeting a Group at High Risk in the Morbidity and Mortality Weekly report (MMWR)* which is available at <u>http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5809a1.htm</u>. The report included three recommendations: 1) Update blood lead screening policies for Medicaid-eligible children; 2) Improve rates of blood lead screening for Medicaid-eligible children determined to be at increased risk for lead exposure; and 3) Design and implement updated surveillance and evaluation strategies. In October 2009, CMS and CDC released a joint memorandum announcing the new CDC recommendations and noted that CMS and CDC were working to update our Medicaid lead screening policy.

Given the information in the CDC report supporting the decrease in the number of children ages 1 to 5 with elevated blood lead levels and the importance of State and local data, adopting the CDC recommendations will allow States' limited resources to be targeted to those children most needing these services. In addition, we believe providers will be more willing to screen children in a targeted group where data supports the risk of lead poisoning rather than being asked to universally screen all Medicaid eligible children and seeing little results. We will also be

increasing our efforts to ensure that Medicaid eligible children who need to be screened for lead poisoning receive the necessary blood lead screening test.

CMS has historically followed CDC recommendations on lead screening for Medicaid eligible children, and this shift in approach is consistent with past practices. However, we understand that this change will not be without challenges. CDC and CMS are developing a process by which State Medicaid Agencies would apply to CDC and CMS for approval to discontinue universal screening and move to the targeted approach. State Medicaid Agencies will need to partner with their State Health Departments and/or lead screening programs to collect and share data needed to support such a change and also to provide new screening guidelines to providers. In States where data on lead exposure are not sufficient, universal screening will need to be continued. We will continue to work closely with States as they work through this transition and will provide further guidance as needed.

The CMS and CDC have developed a preliminary process for State Medicaid Agencies to request to move their Medicaid eligible children into a State specific targeted lead screening approach, and we expect to finalize the process in the coming months. Because a targeted approach will involve data from State Health Departments, we encourage Medicaid agencies who have not already done so to begin working with their State Health Department. Medicaid agencies and State Health Departments will need to ensure that the appropriate data sharing and other cooperative arrangements are in place so that, when the new process is implemented, the State can ensure that Medicaid eligible children are appropriately screened for lead poisoning according to the State's assessment of need. If you have any questions please feel free to contact Cindy Ruff at 410-786-5916 or Cynthia.Ruff@cms.hhs.gov.

Revisions to Managed Care External Quality Review Protocols for Public Comment

The Balanced Budget Act of 1997 (BBA) required State Medicaid agencies that contract with Medicaid managed care organizations (MCOs) to develop a State quality assessment and improvement strategy that is consistent with standards established by the Department of Health and Human Services (HHS). The BBA also requires HHS to develop protocols for use in the performance of independent, external review of the quality and timeliness of, and access to, care and services provided to Medicaid beneficiaries by Medicaid MCOs and prepaid inpatient health plans (PIHPs). CHIP managed care plans also are required to conduct EQRs, as required by the Children's Health Insurance Program Reauthorization Act of 2009.

We published proposed substantial updates to the CMS EQR protocols in a Federal Register Notice on February 17, 2012, available at <u>http://www.gpo.gov/fdsys/pkg/FR-2012-02-17/pdf/2012-3790.pdf</u>. The draft revised EQR Protocols are available for viewing and download at the CMS Medicaid.gov website:

http://www.cms.gov/PaperworkReductionActof1995/PRAL/list.asp - and click on the link <u>CMS-</u> <u>**R-305**</u>. Public comments are due April 17, 2012.